Arcturus Therapeutics Holdings Inc. ARCT R2K
Company Overview
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.13.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $67.22M (-51.4% YoY); net profit $-65.78M.
- Trailing 12 Months Year-on-year growth — revenue -93.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -31.1%, profit CAGR -267.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -31.13% |
| 1 Year: | -93.00% |
Compounded Profit Growth
| 5 Years: | -267.88% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -51.99% |
| 6 Months: | -15.14% |
| 3 Months: | -26.38% |
| 1 Month: | -8.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -31.1% CAGR over 5 years.
- Earnings shrank at -267.9% CAGR over 5 years.
- Trading 72.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARCT Arcturus Therapeutics Holdings Inc. R2K | 6.39 | -2.38 | $181.62M | 0.00% | -28.02% | -37.01% | -31.13% | -267.88% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.39M | 3.42M | 4.35M | 10.15M | 3.32M | 2.97M | 2.65M | 2.32M | 2.33M | 2.24M | 2.13M | 2.00M | 2.44M | 5.79M | 5.24M | 27.09M | 13.37M | 80.28M | 10.52M | 45.14M | 38.01M | 49.86M | - | - | 25.48M | 24.51M | 14.15M | 3.08M | 610.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.30M | 36.13M | 30.66M | 34.39M | 29.54M |
| Operating Income | -10.07M | -4.36M | -6.51M | -572.00K | -7.62M | -10.82M | -9.46M | -10.04M | -20.94M | -31.08M | -57.67M | -53.72M | -53.82M | -37.65M | -50.38M | -22.09M | -36.81M | 14.76M | -55.37M | -19.31M | -30.41M | -21.13M | - | - | -16.83M | -11.62M | -16.51M | -31.31M | -28.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.02M | -10.84M | -15.75M | -20.14M | -28.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.08M | -9.18M | -13.45M | -29.08M | -26.96M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.00K | 0 | 4.00K | 0 | -4.00K | - |
| Net Income | -9.95M | -4.25M | -6.88M | -685.00K | -7.43M | -10.99M | -9.78M | -10.26M | -21.00M | -31.10M | -56.35M | -54.58M | -54.08M | -38.66M | -51.17M | -21.56M | -35.27M | 50.75M | -52.55M | -16.22M | -26.82M | -17.22M | - | - | -14.08M | -9.18M | -13.45M | -29.08M | -26.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -2.07 | -2.05 | - | -1.94 | -0.82 | -1.33 | 1.87 | -1.98 | -0.61 | -1.00 | -0.64 | - | - | -0.52 | -0.34 | -0.49 | -1.03 | -0.95 |
| R&D Expense | 4.22M | 3.97M | 7.32M | 7.27M | 7.05M | 11.99M | 7.92M | 7.94M | 17.70M | 24.29M | 50.05M | 45.68M | 45.40M | 32.63M | 44.89M | 38.19M | 37.69M | 51.77M | 52.67M | 51.08M | 53.57M | 58.67M | 39.13M | - | 34.89M | 29.58M | 23.27M | - | 21.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.75M | 20.79M | 9.54M | - | 205.75M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 193.58M | 235.95M | 234.06M | 143.48M |
| Operating Income | -21.81M | -25.51M | -71.52M | - | 12.18M | -78.20M | -95.67M | -76.26M |
| EBITDA | - | - | - | - | 13.70M | -24.16M | -77.40M | -62.75M |
| Interest Expense | - | - | - | - | 3.00M | 768.00K | 0 | 9.00K |
| Pretax Income | - | - | - | - | 10.64M | -27.89M | -80.94M | -65.78M |
| Tax Provision | - | - | - | - | 1.29M | 1.83M | -4.00K | 0 |
| Net Income | -21.79M | -25.99M | -72.15M | - | 9.35M | -29.73M | -80.94M | -65.78M |
| Diluted EPS | - | - | - | - | 0.35 | -1.00 | -3.00 | -2.40 |
| R&D Expense | 16.98M | 33.64M | 57.85M | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.20M | 82.14M | 476.46M | - | 450.39M | 429.40M | 344.07M | 271.15M |
| Current Assets | - | - | - | - | - | 403.33M | 386.59M | 305.98M | 241.45M |
| Cash & Equivalents | - | 36.71M | 71.35M | 462.89M | - | 391.88M | 292.00M | 237.03M | 230.91M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 2.76M | 32.06M | 3.97M | 5.56M |
| Total Liabilities | - | 30.56M | 56.35M | 79.90M | - | 180.07M | 150.89M | 103.09M | 57.16M |
| Current Liabilities | - | 12.58M | 21.32M | 49.52M | - | 126.98M | 81.99M | 65.49M | 36.38M |
| Long Term Debt | - | 9.91M | 14.99M | 13.85M | 40.63M | - | - | - | - |
| Total Debt | - | - | - | - | - | 94.75M | 30.22M | 28.55M | 25.00M |
| Total Equity | 33.79M | 13.64M | 25.79M | 396.55M | - | 270.31M | 278.51M | 240.98M | 213.99M |
| Shares Outstanding | - | - | - | - | - | 26.55M | 26.83M | 27.00M | 28.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.76M | -6.45M | -42.86M | - | 31.99M | -18.10M | -59.75M | -74.27M |
| Investing Cash Flow | 22.13M | -818.00K | -1.74M | - | -7.73M | -2.90M | -648.00K | -230.00K |
| Financing Cash Flow | 10.20M | 41.91M | 436.14M | - | -2.86M | -24.09M | 5.42M | 13.38M |
| Capital Expenditure | -1.48M | -818.00K | -1.74M | - | -7.73M | -2.90M | -648.00K | -230.00K |
| Free Cash Flow | -22.24M | -7.26M | -44.60M | - | 24.27M | -21.00M | -60.40M | -74.50M |
| Net Change in Cash | - | - | - | - | 21.41M | -45.09M | -54.98M | -61.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -138.5% | -122.7% | -749.8% | - | 5.9% | -49.6% | -69.1% | -113.4% |
| Net Margin % | -138.3% | -125.0% | -756.3% | - | 4.5% | -18.8% | -58.5% | -97.9% |
| ROE % | -159.7% | -100.8% | -18.2% | - | 3.5% | -10.7% | -33.6% | -30.7% |
| ROCE % | -69.0% | -41.9% | -16.8% | - | 3.8% | -22.5% | -34.3% | -32.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 11.62% | 3.30M | $21.04M |
| 2 | ARK Investment Management, LLC | 9.74% | 2.77M | $17.64M |
| 3 | Blackrock Inc. | 9.19% | 2.61M | $16.65M |
| 4 | Sumitomo Mitsui Trust Group, Inc. | 8.05% | 2.29M | $14.58M |
| 5 | Amova Asset Management Americas Inc | 8.05% | 2.29M | $14.58M |
| 6 | Vanguard Capital Management LLC | 3.89% | 1.11M | $7.05M |
| 7 | Two Sigma Investments, LP | 3.81% | 1.08M | $6.89M |
| 8 | Vanguard Portfolio Management LLC | 3.44% | 977.92K | $6.23M |
| 9 | Geode Capital Management, LLC | 2.33% | 660.93K | $4.21M |
| 10 | State Street Corporation | 1.91% | 543.86K | $3.46M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARCT
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
SAN DIEGO, July 02, 2026--Arcturus Therapeutics Holdings Inc. ("Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collabora…
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New …
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
Moby summary of Arcturus Therapeutics Holdings Inc.'s Q1 2026 earnings call
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?…
Arcturus Therapeutics Q1 Earnings Call Highlights
Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress in two rare-disease clinical programs and outlined a strengthened cash runway during the company’s first-quarter 2026 earnings call, while also discussing ongoing partner a…
ARCT — Frequently Asked Questions
What is the current share price of Arcturus Therapeutics Holdings Inc. (ARCT)?
As of 2026-07-15 16:51 PDT, Arcturus Therapeutics Holdings Inc. (ARCT) trades at $6.39 on NasdaqGM. Its 52-week range is $5.90 to $23.16.
What is the market capitalisation of ARCT?
Arcturus Therapeutics Holdings Inc. (ARCT) has a market capitalisation of $181.62M on NasdaqGM.
What is the P/E ratio of ARCT?
ARCT trades at a trailing price-to-earnings (P/E) ratio of -2.38. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 0.95.
What is the return on equity (ROE) of ARCT?
ARCT has a return on equity (ROE) of -37.01%. Its return on capital employed (ROCE) is -28.02%.
Is ARCT a good stock to buy?
This page provides a data-driven analysis of Arcturus Therapeutics Holdings Inc. (ARCT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.